Pfizer Inc.'s Temsirolimus Plus Roche’s Bevacizumab Not Recommended for First-Line RCC

CHICAGO (EGMN) – The combination of two standard treatments, temsirolimus and bevacizumab, dramatically increased toxicity without any signal of increased efficacy in the first-line treatment of metastatic kidney cancer in the phase II TORAVA trial.